Explore the neurobiology and clinical management of agitation in Alzheimer's dementia. Test your knowledge on approved pharmacotherapy mechanisms, landmark trial outcomes, long-term durability, and caregiver impact.
5 questions
Which receptor profile makes a serotonin-dopamine activity modulator suitable for agitation in Alzheimer's dementia?
Correct Answer: A
Brexpiprazole acts as a partial agonist at serotonin 5-HT1A and dopamine D2/D3 receptors and as an antagonist at 5-HT2A and several adrenergic receptors. It has lower affinity for H1 and M1 receptors than for its principal monoaminergic targets. The exact mechanism for efficacy in agitation associated with dementia due to Alzheimer's disease is unknown.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d301358-6291-4ec1-bd87-37b4ad9bd850
12-week active-treatment extension trial (J Alzheimers Dis 2024): What was the response durability finding for brexpiprazole in AD agitation?
Correct Answer: B
The 2024 extension trial confirmed sustained, clinically meaningful response — defined as at least 20-point CMAI total score reduction — over 24 weeks at a consistent rate of improvement, supporting long-term treatment for this chronic, recurring symptom.
https://pubmed.ncbi.nlm.nih.gov/38709695/
AAIC 2024 post-hoc pooled analyses: Which agitation behaviors showed the greatest reduction vs placebo?
Correct Answer: C
AAIC 2024 post-hoc analyses showed brexpiprazole produced greater reductions in restlessness, pacing, and cursing vs placebo. Among behaviors rated most bothersome by caregivers, greater reductions were also observed — suggesting meaningful caregiver burden relief.
https://otsuka-us.com/news/otsuka-and-lundbeck-present-new-rexultir-brexpiprazole-post-hoc-efficacy-data-analyses
What class-wide safety warning must be considered when prescribing any atypical antipsychotic to elderly patients with dementia?
Correct Answer: D
All atypical antipsychotics carry a black box warning for increased mortality in elderly patients with dementia-related psychosis, based on postmarketing surveillance data showing increased cardiovascular and infectious death vs placebo. This risk must be weighed against the burden of severe agitation.
What distinction does brexpiprazole hold in its approved indication for Alzheimer's disease?
Brexpiprazole received FDA approval in May 2023 as the first and only treatment approved specifically for agitation associated with dementia due to Alzheimer's disease — filling a long-standing pharmacotherapy gap despite agitation being one of the most prevalent neuropsychiatric symptoms in AD.
https://www.fda.gov/drugs/drug-approvals-and-databases/nda-214369
Start your journey with Neurologist Connect
